NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The company has laboratory locations in Ft. Myers and Tampa, Florida; Irvine, California; and Nashville, Tennessee. Testing Services The company offers the following types of testing services: Cytogenetics testing - the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetic studies are often utilized to answer diagnostic, prognostic and predictive questions in the treatment of hematological malignancies and solid tumors; Fluorescence In-Situ Hybridization (FISH) testing - a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes. FISH helps bridge abnormality detection between the chromosomal and DNA sequence levels; Flow cytometry testing - a rapid way to measure the characteristics of cell populations. Cells from peripheral blood, bone marrow aspirate, lymph nodes, and other areas are labeled with selective fluorescent antibodies and quantified according to their surface antigens. These fluorescent antibodies bind to specific cell surface antigens and are used to identify malignant cell populations. Flow cytometry is performed in conjunction with morphology testing which looks at smears on glass slides for abnormal cell populations; Immunohistochemistry (IHC) testing - the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens. IHC is also used to understand the distribution and localization of differentially expressed proteins; and Molecular testing - a cancer diagnostic tool focusing on the analysis of DNA and RNA, as well as the structure and function of genes at the molecular level. All of these testing services are utilized to determine the diagnosis and prognosis of various types and subtypes of cancer and to help predict a patient’s potential response to specific therapies. The company offers testing services on both a ‘tech-only’ basis, where it performs the technical component of the testing (specimen set-up, staining, imaging, sorting and categorization of cells, chromosomes, genes or DNA) and the client physician performs the related professional interpretation component (analyzing the laboratory data, viewing the cells, developing the diagnosis or prognosis, as well as preparing and writing the final report), as well as on a full service or ‘global’ basis where the company performs both the technical component and its medical staff provides the professional interpretation component. Global Service Offerings The company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. Its Genetic Pathology Solutions (GPS) report summarizes all relevant case data from global services on one summary report. When providing global services, the company performs both the technical and professional component of the test, which results in a higher reimbursement level. Seasonality The volume of testing services declines modestly during the summer vacation season, year-end holiday periods and other major holidays, particularly when those holidays fall during the middle of the week. Suppliers The company orders its laboratory and research supplies from large national laboratory supply companies such as Abbott Laboratories, Fisher Scientific, Life Technologies, Metasystems, Invitrogen, Cardinal Health, Ventana and Beckman Coulter. Customers The company markets its services to pathologists, oncologists, urologists, other clinicians, hospitals and other clinical laboratories. Trademarks The ‘NeoGenomics’ name and logo has been trademarked with the United States Patent and Trademark Office. The company has also trademarked or has applications pending for the brand names NeoFISH, NeoFlow, NeoSITE, NeoArray, NeoType, MelanoSITE, NeoSCORE and NeoLINK. The company has also trademarked the marketing slogans, ‘When time matters and results count’ and ‘Time matters, results count’. Significant Events In January 2015, NeoGenomics Inc. has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, or Lurie Cancer Center, and the Northwestern Medicine Developmental Therapeutics Institute, or NMDTI, to initiate a translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics. History NeoGenomics, Inc. was founded in 2001.
(NEO:Consolidated Issue listed on NASDAQ Capital Market)
12701 Commonwealth Drive
Fort Myers, FL 33913
|Cancer Genetics Inc||$10.70 USD||+0.3899|
|Enzo Biochem Inc||$2.46 USD||+0.03|
|Psychemedics Corp||$14.57 USD||+0.26|
|Response Genetics Inc||$0.37 USD||+0.041|
|Rosetta Genomics Ltd||$3.72 USD||+0.06|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.